✦ LIBER ✦

O-2 TWO second-line docetaxel dose-schedules in advanced non-small-cell lung cancer (NSCLC): A Spanish lung cancer group (SLCG) phase III trial

✍ Scribed by Camps, Carlos; Massuti, Bartomeu; Jimenez, Ana Maria; Batista, Noberto; Galan, Antonio; Isla, Dolores; Blanco, Remedios; Carrato, Alfredo; Garcia, Carlos; Rosell, Rafael

Book ID: 118571393
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 188 KB
Volume: 41
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(03)91660-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PD-069 Quality-of-Life (COL) assessment

PD-069 Quality-of-Life (COL) assessment in two docetaxel dose-schedulesas second-line treatment of advanced non small cell lung cancer (NSCLC): Spanish Lung Cancer Group (SLCG) Phase III trial

✍ Camps, C.; Massuti, B.; Jiménez, A.; Maestu, I.; Garcia, R.; Isla, M.; González- 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 277 KB

Phase II trial of weekly docetaxel (D) i

Phase II trial of weekly docetaxel (D) in second-line non-small cell lung cancer (NSCLC)

✍ Lilenbaum, R; Schwartz, M; Siegel, L; Belette, F; Blaustein, A; Wittlin, F; Cisn 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 114 KB

O-1 A phase III trial comparing weekly a

O-1 A phase III trial comparing weekly and three weekly docetaxel in second line treatment of patients with advanced non small cell lung cancer (NSCLC)

✍ Schuette, Wolfgang; Nagel, Sylke; Lautenschlaeger, C.; Serke, Monika; Wollschlae 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Phase III trial of docetaxel (D) and car

Phase III trial of docetaxel (D) and carboplatin (CBDCA) as first-line chemotherapy in advanced non-small cell lung cancer (NSCLC)

✍ Giannakakis, Th; Mavroudis, D; Papadouris, S; Kourousis, Ch; Ziras, N; Kakolyris 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 224 KB

Phase III trial comparing paclitaxel pol

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

✍ Paz-Ares, L; Ross, H; O'Brien, M; Riviere, A; Gatzemeier, U; Von Pawel, J; Kauke 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 143 KB

O-099 XYOTAX™ vs. docetaxel for the seco

O-099 XYOTAX™ vs. docetaxel for the second-line treatment of non-small cell lung cancer (NSCLC): The STELLAR 2 phase III study

✍ Bonomi, P.; Paz-Ares, L.; Langer, C.; O'Brien, M.; Gervais, R.; Gatzemeier, U.; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 131 KB